189 related articles for article (PubMed ID: 15140424)
1. The AGE of the matrix: chemistry, consequence and cure.
DeGroot J
Curr Opin Pharmacol; 2004 Jun; 4(3):301-5. PubMed ID: 15140424
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis.
DeGroot J; Verzijl N; Wenting-van Wijk MJ; Jacobs KM; Van El B; Van Roermund PM; Bank RA; Bijlsma JW; TeKoppele JM; Lafeber FP
Arthritis Rheum; 2004 Apr; 50(4):1207-15. PubMed ID: 15077303
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
4. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H
Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
6. Aging cartilage and osteoarthritis--what's the link?
Loeser RF
Sci Aging Knowledge Environ; 2004 Jul; 2004(29):pe31. PubMed ID: 15272115
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring inhibitors against the formation of advanced glycation end-products.
Peng X; Ma J; Chen F; Wang M
Food Funct; 2011 Jun; 2(6):289-301. PubMed ID: 21779567
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of advanced glycation end products decreases collagen turnover by bovine chondrocytes.
DeGroot J; Verzijl N; Budde M; Bijlsma JW; Lafeber FP; TeKoppele JM
Exp Cell Res; 2001 Jun; 266(2):303-10. PubMed ID: 11399058
[TBL] [Abstract][Full Text] [Related]
9. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
10. The Maillard reaction and its consequences for a living body.
Sztanke K; Pasternak K
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):159-62. PubMed ID: 15323185
[TBL] [Abstract][Full Text] [Related]
11. epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis.
Schmitt HP
Med Hypotheses; 2006; 66(5):898-906. PubMed ID: 16442744
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation endproducts and cigarette smoking.
Nicholl ID; Bucala R
Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1025-33. PubMed ID: 9846884
[TBL] [Abstract][Full Text] [Related]
13. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia.
Osawa T; Kato Y
Ann N Y Acad Sci; 2005 Jun; 1043():440-51. PubMed ID: 16037265
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end product (age) inhibitors and their therapeutic implications in diseases.
Takeuchi M; Yamagishi S; Iwaki M; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2004; 24(2-3):95-101. PubMed ID: 15689055
[TBL] [Abstract][Full Text] [Related]
15. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
16. Age-related changes in the glycation of human aortic elastin.
Konova E; Baydanoff S; Atanasova M; Velkova A
Exp Gerontol; 2004 Feb; 39(2):249-54. PubMed ID: 15036419
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases.
Grillo MA; Colombatto S
Amino Acids; 2008 Jun; 35(1):29-36. PubMed ID: 18008028
[TBL] [Abstract][Full Text] [Related]
18. Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes.
Yamagishi S; Matsui T; Nakamura K
Med Hypotheses; 2008 Dec; 71(6):876-8. PubMed ID: 18783891
[TBL] [Abstract][Full Text] [Related]
19. New therapies for advanced glycation end product nephrotoxicity: current challenges.
Williams ME
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S42-7. PubMed ID: 12612951
[TBL] [Abstract][Full Text] [Related]
20. TAGE (toxic AGEs) hypothesis in various chronic diseases.
Takeuchi M; Yamagishi S
Med Hypotheses; 2004; 63(3):449-52. PubMed ID: 15288366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
